NCT00787267View on ClinicalTrials.gov

Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Dasatinib

70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.

Trial Locations (3)

27609

Duke Raleigh, Raleigh

27705

Durham VA Medical Center, Durham

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Duke University

OTHER

NCT00787267 - Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC | Biotech Hunter | Biotech Hunter